

Supplemental Table for:

The Impact of Anlotinib on Brain Metastases of NSCLC: Post-hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)

Hengrui Liang et al.

Supplementary Table S1. The brain-associated toxicities

	Anlotinb n=294			Placebo n=143		
	BM	Non-BM	Total	BM	Non-BM	Total
Mental disorder	8	37	45	3	17	20
Upset	0	1	1	0	0	0
Anxiety	5	27	32	0	12	12
Insomnia	7	24	31	1	14	15
Drowsiness	1	5	6	2	3	5
Depressed	0	1	1	0	0	0
Suicidal tendency	0	0	0	0	1	1
Delusion	0	1	1	0	0	0
Nervous system diseases	21	65	86	6	14	20
Headache	6	28	34	1	4	5
Dizzy	9	25	34	4	9	13
Unconscious	5	2	7	0	0	0
Aphasia	0	1	1	0	0	0
Facial paralysis	1	0	1	0	0	0
Cerebral hemorrhage	1	0	1	1	0	1
Cerebral thromboembolic	1	2	3	0	0	0
Metastatic tumor hemorrhage	1	0	1	0	0	0
Cerebral edema	0	0	0	1	1	2
Epileptic seizure	2	1	3	1	0	1
Pulmonary encephalopathy	0	1	1	0	0	0
Paresthesia	2	12	14	1	4	5
Dysgeusia	0	1	1	0	0	0
Peripheral nervous disturbance	0	1	1	1	0	1
Hypomnesia	0	7	7	0	0	0
Epileptic seizure (Grade 3)	0	1	1	0	0	0
Suicidal tendency (Grade 3)	0	0	0	0	1	1
Cerebral hemorrhage (Grade 3)	1	0	1	0	0	0
Unconscious (Grade 4)	4	0	4	0	0	0
Pulmonary encephalopathy (Grade 4)	0	1	1	0	0	0
Cerebral edema (Grade 4)	0	0	0	1	0	1
Cerebral hemorrhage (Grade 5)	0	0	0	1	0	1

BM, brain metastasis